Trump says Pfizer will sell some drugs at 'most‑favored nation' prices, claiming 50–100% cuts
President Trump announced a federal drug‑pricing website, TrumpRx.gov, to launch in 2026 and said an agreement with Pfizer would let some medicines be sold at a “most‑favored nation” cost, claiming price cuts of 50–100%. Pfizer told reporters its direct‑to‑consumer prices on the portal will be “50% lower on average” though terms are confidential; the discounts would apply to purchases made outside insurance through companies’ fulfillment sites, and experts warn the plan may offer little relief for insured patients and that programs like Medicaid already pay low prices.
Economy
Politics
Health
Corporate News
🔍 Key Facts
- President Trump said some medications will be sold at a 'most‑favored nation' cost under a deal with Pfizer and claimed some drug prices could fall by 50%–100%.
- Pfizer told reporters that prices on the new direct‑to‑consumer portal will be '50% lower on average' according to a company press release, but specific terms of the agreement remain confidential.
- The White House announced a federal website, TrumpRx.gov, to launch in 2026 that will route consumers to discounted direct‑to‑consumer drug purchases and direct orders to pharmaceutical companies' own fulfillment sites.
- Administration officials said the announced discounts would be available to patients not using insurance (cash or uninsured purchasers) rather than to insured consumers through their plans.
- Named officials present at the Oval Office briefing included CMS Administrator Mehmet Oz, FDA Commissioner Martin Makary, HHS Secretary Robert F. Kennedy Jr., and Pfizer CEO Albert Bourla.
- Expert reaction (Ameet Sarpatwari, Harvard) cautioned the plan may be underwhelming for average insured consumers and noted that Medicaid already pays low prices for many drugs.
📍 Contextual Background
- On 2025-09-22, President Donald Trump publicly stated that acetaminophen (Tylenol) "can be associated with a very increased risk of autism" and linked Tylenol with autism.
- An FDA press release stated that some studies have found an association between acetaminophen and autism but those studies have not established causation.
- On 2025-09-22, the U.S. Food and Drug Administration (FDA) said it would begin the process of updating the safety label for Tylenol and acetaminophen.
- At the 2025-09-22 White House press conference where President Trump linked acetaminophen to autism, the individuals reported as flanking him included Jay Bhattacharya, Marty Makary, Robert F. Kennedy Jr., and Mehmet Oz.
📰 Sources (3)
President announces TrumpRx website for drugs, and pricing deal with Pfizer
New information:
- White House announced a federal website, TrumpRx.gov, to route consumers to discounted direct‑to‑consumer drug purchases; site to launch in 2026.
- Pfizer told reporters its direct‑to‑consumer prices on the portal will be '50% lower on average' per a company press release; specific terms of the agreement remain confidential.
- Administration officials said the discounts would be available to patients not using insurance and the website would direct orders to pharmaceutical companies' own direct‑to‑consumer fulfillment sites.
- Named officials present at the Oval Office briefing: CMS Administrator Mehmet Oz, FDA Commissioner Martin Makary, HHS Secretary Robert F. Kennedy Jr., and Pfizer CEO Albert Bourla.
- Reporting includes expert reaction (Ameet Sarpatwari, Harvard) cautioning the plan may be underwhelming for average insured consumers and explaining Medicaid already pays low prices.
Trump says some medications will be sold at reduced "most-favored nation cost" in Pfizer deal
New information:
- President Trump said some medications will be sold at a 'most‑favored nation cost' under a deal with Pfizer.
- The president claimed some drug prices could fall by 50%–100%.